RDY

Dr.Reddys
NYSE

Real-time Quotes | Nasdaq Last Sale

52.01
+0.45
+0.87%
After Hours: 52.01 0 0.00% 16:00 07/10 EDT
OPEN
51.55
PREV CLOSE
51.56
HIGH
52.17
LOW
51.51
VOLUME
147.50K
TURNOVER
--
52 WEEK HIGH
55.19
52 WEEK LOW
33.33
MARKET CAP
8.62B
P/E (TTM)
33.82
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Underperform

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RDY stock price target is 42.25 with a high estimate of 45.00 and a low estimate of 39.50.

EPS

RDY News

More
India's Cipla set to undercut rivals with generic remdesivir -sources
Reuters · 2d ago
Here's Why Amarin Tumbled 67.7% in the First Half of 2020
MotleyFool.com · 2d ago
Mylan to launch generic remdesivir version in India at $64 per 100 mg vial
Reuters · 4d ago
Hedge Funds Are Selling Dr. Reddy’s Laboratories Limited (RDY)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds
Insider Monkey · 5d ago
Fujifilm inks deal for Avigan for potential treatment of COVID-19
Seeking Alpha - Article · 07/01 10:09
Dr. Reddy’s Partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a Potential Treatment of COVID-19
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, hereafter referred to as "Dr. Reddy’s") announces partnering with FUJIFILM Corporation through FUJIFILM Toyama Chemical Co. Ltd. (hereafter referred to as "FUJIFILM") and Global Response Aid
Business Wire · 07/01 08:10
Dr. Reddy's Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga® (
Business Wire · 06/19 09:39
Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'
Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa. 
Benzinga · 06/17 15:52

Industry

Pharmaceuticals
-0.37%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About RDY

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.
More

Webull offers kinds of Dr.Reddy's Laboratories Ltd (ADR) stock information, including NYSE:RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.